Merck & Co (MRK) Q1 2025 Earnings Call April 24, 2025 04:19 PM ET Company Participants Peter Dannenbaum - Senior VP of Investor RelationsRobert Davis - Chairman & CEOCaroline Litchfield - Executive VP & CFODean Li - EVP & President;, Merck Research LaboratoriesGeoff Meacham - Managing DirectorLuisa Hector - Head of Global Pharma Equity ResearchChris Schott - Managing DirectorJames Shin - Director of Biopharma Equity ResearchAlexandria Hammond - Director, Head of TherapeuticsUmer Raffat - Senior Managing Dir ...

Merck (MRK) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.22, which beat the Zacks Consensus Estimate of $2.15. Earnings rose 7% year over year on a reported basis and 12% excluding foreign exchange (Fx). This upside was primarily driven by a one-time charge incurred by the company in the year-ago quarter for the acquisition of Harpoon Therapeutics, which was completed in March 2024.Revenues declined 2% year over year (up 1% excluding Fx) to $15.53 billion. Sales also beat the Zacks Co ...

First-Quarter 2025 Sales and Earnings Merck & Co., Inc., Rahway, N.J., USA April 24, 2025 Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Question & Answer Session Agenda Agenda 2 Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., In ...

Merck & Co., Inc. (NYSE:MRK) Q1 2025 Earnings Conference Call April 24, 2025 9:00 AM ET Corporate Participants Peter Dannenbaum - Senior Vice President, Investor Relations Rob Davis - Chairman and Chief Executive Officer Caroline Litchfield - Chief Financial Officer Dean Li - President of Merck Research Labs Conference Call Participants Geoff Meacham - Citi Tim Anderson - Bank of America Luisa Hector - Berenberg Vamil Divan - Guggenheim Securities Chris Schott - JPMorgan James Shin - Deutsche Bank Steve Sca ...

For the quarter ended March 2025, Merck (MRK) reported revenue of $15.53 billion, down 1.6% over the same period last year. EPS came in at $2.22, compared to $2.07 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $15.39 billion, representing a surprise of +0.93%. The company delivered an EPS surprise of +3.26%, with the consensus EPS estimate being $2.15.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they co ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Pharmaceutical giant Merck & Co Inc (NYSE:MRK) has reversed its premarket lead, down 2% at $77.20 at last glance. The company posted better-than-expected first-quarter results but cut its profit outlook, expecting a $200 million dent from tariffs. Creeping back down toward its April 16 three-year low of $75.95, MRK is down 22.7% since the start of the year. So far today, MRK has seen 21,000 calls and 29,000 puts exchanged -- triple the overall options volume typically seen at this point. The May 75 put is t ...

Exhibit 99.1 News Release Merck Announces First-Quarter 2025 Financial Results RAHWAY, N.J., April 24, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025. "Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline," said Robert M. Davis, chairman and chief executive officer, Merck. "We are working with ...

Core Viewpoint - Merck has lowered its full-year profit guidance due to estimated costs from tariffs and a one-time charge related to a recent deal, impacting its adjusted earnings outlook for 2025 [1][4]. Financial Guidance - The company now expects adjusted earnings for 2025 to be between $8.82 and $8.97 per share, a decrease from the previous range of $8.88 to $9.03 per share [1]. - Merck reiterated its full-year sales forecast of between $64.1 billion and $65.6 billion [4]. Tariff Impact - The expected tariff charge is primarily due to levies between the U.S. and China, with additional impacts from Canada and Mexico [2]. - The new outlook does not include the potential effects of President Trump's planned tariffs on pharmaceuticals imported into the U.S., which may lead to increased U.S. manufacturing investments by drugmakers [3]. Investment in U.S. Manufacturing - Merck has invested $12 billion in U.S. manufacturing and research and development, with plans to invest an additional $9 billion by the end of 2028 [3]. Recent Financial Performance - In the first quarter, Merck reported net income of $5.08 billion, or $2.01 per share, compared to $4.76 billion, or $1.87 per share, in the same period last year [6]. - The company earned $2.22 per share excluding acquisition and restructuring costs, surpassing the expected $2.14 [8]. Revenue Performance - Merck's revenue for the first quarter was $15.53 billion, a 2% decrease from the same period a year ago, but above the expected $15.31 billion [7][8]. Product Contributions - The company noted significant sales contributions from two recently launched drugs, Winrevair and Capvaxive, which are expected to help offset losses from its top-selling cancer therapy, Keytruda, set to lose exclusivity in 2028 [5].

Merck & Co Inc MRK will be reporting its first-quarter earnings on Thursday before the market opens. Wall Street expects earnings per share of $2.14 and revenue of $15.33 billion.The stock is down a painful 38.04% over the past year and has dropped 20.73% year-to-date. Even in the past month, it’s off by 14.85%, making it one of the more bruised names among Big Pharma peers.Let's look at what the charts indicate for Merck stock and how it currently maps against Wall Street estimates.Read Also: Gilead Cancer ...